These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Placebo-controlled n-of-1 trials in cystic fibrosis. Webb S; Tansey P; Brown H; Jackson A; Bilton D Eur Respir J; 1999 Oct; 14(4):993; author reply 994. PubMed ID: 10573255 [No Abstract] [Full Text] [Related]
3. Ivacaftor for cystic fibrosis. Barry PJ; Donaldson AL; Jones AM BMJ; 2018 May; 361():k1783. PubMed ID: 29773589 [No Abstract] [Full Text] [Related]
4. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. Aitken ML; Burke W; McDonald G; Shak S; Montgomery AB; Smith A JAMA; 1992 Apr; 267(14):1947-51. PubMed ID: 1548827 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Phung OJ; Coleman CI; Baker EL; Scholle JM; Girotto JE; Makanji SS; Chen WT; Talati R; Kluger J; White CM Pediatrics; 2010 Nov; 126(5):e1211-26. PubMed ID: 20921071 [TBL] [Abstract][Full Text] [Related]
6. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Johnson JA; Connolly MA; Jacobs P; Montgomery M; Brown NE; Zuberbuhler P Pharmacotherapy; 1999 Oct; 19(10):1159-66. PubMed ID: 10512065 [TBL] [Abstract][Full Text] [Related]
7. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Eisenberg JD; Aitken ML; Dorkin HL; Harwood IR; Ramsey BW; Schidlow DV; Wilmott RW; Wohl ME; Fuchs HJ; Christiansen DH; Smith AL J Pediatr; 1997 Jul; 131(1 Pt 1):118-24. PubMed ID: 9255202 [TBL] [Abstract][Full Text] [Related]
8. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
10. Mucolytic therapy in cystic fibrosis. Wallis C J R Soc Med; 2001; 94 Suppl 40(Suppl 40):17-24. PubMed ID: 11601159 [No Abstract] [Full Text] [Related]
11. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems. Zach MS Thorax; 1996 Jul; 51(7):750-5. PubMed ID: 8882085 [No Abstract] [Full Text] [Related]
12. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Milla CE Thorax; 1998 Dec; 53(12):1014-7. PubMed ID: 10195070 [TBL] [Abstract][Full Text] [Related]
13. DNase in cystic fibrosis: the challenge of assessing response and maximising benefit. Innes JA Thorax; 1998 Dec; 53(12):1003-4. PubMed ID: 10195066 [No Abstract] [Full Text] [Related]
14. [Cystic fibrosis: current therapy. Inhalation therapy with recombinant DNAse]. Rutishauser M Schweiz Med Wochenschr Suppl; 2000; 122():47S-48S. PubMed ID: 12536474 [No Abstract] [Full Text] [Related]
15. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F; Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Glutathione for Patients With Cystic Fibrosis: A Meta-analysis of Randomized-Controlled Studies. Zhao J; Huang W; Zhang S; Xu J; Xue W; He B; Zhang Y Am J Rhinol Allergy; 2020 Jan; 34(1):115-121. PubMed ID: 31550169 [No Abstract] [Full Text] [Related]
17. Which DNAse in cystic fibrosis? Morice AH Lancet; 1993 Sep; 342(8871):624-5. PubMed ID: 8102760 [No Abstract] [Full Text] [Related]
18. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. George PM; Banya W; Pareek N; Bilton D; Cullinan P; Hodson ME; Simmonds NJ BMJ; 2011 Feb; 342():d1008. PubMed ID: 21357627 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE; Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017 [TBL] [Abstract][Full Text] [Related]